Cell viability analyses showed that GBM tumor-derived ECs were resistant to pharmacological inhibition of VEGFR (Fig. 1a) and B20 antibody-mediated blockade of VEGF (Fig. 1b). This evidence concerns the gene VEGFA and neoplasm.